Treatment of Mild Systemic Lupus Erythematosus Without Renal Involvement
This protocol covers the clinical management of mild SLE in patients without renal involvement.
It applies to a clearly defined low-activity disease state, with the overarching goal of achieving
remission or sustained low disease activity.
Clinical Scenario
Patients in this category present with mild, non-renal manifestations of lupus. The defining features are:
- Constitutional symptoms and/or mild arthritis
- Rash affecting ≤9% of body surface area
- Platelet count 50–100 × 10&sup9;/L
- SLEDAI ≤6
- BILAG C, or at most one BILAG B manifestation
Treatment Goals
The primary targets are a SLEDAI score of 0 (full remission) or, where remission is not immediately
achievable, a SLEDAI ≤4 representing a low disease activity state.
Treatment Approach — partial overview
Management in this setting includes an antimalarial agent recommended for eligible patients as a
cornerstone of therapy, with glucocorticoids considered as an adjunct when additional control of
disease activity is required. The complete regimen — including individualisation criteria,
sequencing, and tapering strategy — is available in the full protocol.
References
DOI: 10.1136/ard-2023-224762
- Mild disease: constitutional symptoms; mild arthritis; rash ≤9% body surface area; platelet count (PLTs) 50–100 × 10&sup9;/L; SLEDAI≤6; BILAG C or ≤1 BILAG B manifestation.
- Hydroxychloroquine is recommended for all patients (1b/A), unless contraindicated, at a target dose of 5 mg/kg real body weight/day (2b/B), but individualised based on risk for flare (2b/B) and retinal toxicity.
- Glucocorticoids, if needed, are dosed based on the type and severity of organ involvement (2b/C), and should be reduced to maintenance dose of ≤5 mg/day (prednisone equivalent) (2a/B) and, when possible, withdrawn.
View source ↗